Oncology - Tumor Targeting

We have developed a panel of fully human antibodies against a well-established, clinically and commercially validated target that is important for tumor growth and expansion. While antibodies against this factor have been developed in the past, we believe that the existing products and product candidates have limitations that our product candidates could overcome.

In addition, in contrast to existing competing product candidates, our product will be a fully human antibody with the potential for improved performance in patients.

This antibody is currently still in lead optimization and we have not yet disclosed the molecular target.